Journal of Neuroimmunology
Volume 178, Issue 1 , Pages 76-86 , September 2006

PPARγ antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-Deoxy-Δ12,14-Prostaglandin J2

  • Himanshu P. Raikwar

      Affiliations

    • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    • ,
  • Gladson Muthian

      Affiliations

    • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    • ,
  • Johnson Rajasingh

      Affiliations

    • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    • ,
  • Caroline N. Johnson

      Affiliations

    • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    • ,
  • John J. Bright

      Affiliations

    • Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    • Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    • Methodist Research Institute, Clarian Health Partners, Indianapolis, IN 46202, USA
    • Corresponding Author InformationCorresponding author. Methodist Research Institute, Clarian Health Partners 1800 N Capital Ave, Noyes Bldg E-504C, Indianapolis, IN 46202, USA. Tel.: +1 317 962 8722; fax: +1 317 962 9369.

Received 5 October 2005 ,Revised 24 April 2006 ,Accepted 16 May 2006.

References 

  1. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell. 1999;4:585–595
  2. Barroso IM, Gurnell VE, Crowley M, Agostini M, Schwabe JW, Soos MA, et al. Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880–883
  3. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J. Clin. Endocrinol. Metab. 2005;90:3886–3896
  4. Bitsch A, Bruck W. Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs. 2002;6:405–418
  5. Blumberg B, Evans RM. Orphan nuclear receptors: new ligands and new possibilities. Genes Dev. 1998;12:3149–3155
  6. Bright JJ, Musuro BF, Du C, Sriram S. Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalomyelitis. J. Neuroimmunol. 1998;82:22–30
  7. Bright JJ, Rodriguez M, Sriram S. Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced CNS demyelination. J. Virol. 1999;3:1637–1639
  8. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001;7:48–52
  9. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;6924:744–748
  10. Coleman MP, Perry VH. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 2002;25:532–537
  11. Demetri GD, Fletcher CD, Mueller E, Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. U. S. A. 1999;96:3951–3956
  12. Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 2002;168:2508–2515
  13. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem. Biophys. Res. Commun. 1996;224:431–437
  14. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U. S. A. 1998;95:8806–8811
  15. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895
  16. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, et al. Peroxisome proliferator activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 2002;51:694–702
  17. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman B, Evans RM. 15-Deoxy-12,14 prostaglandin J2 a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–812
  18. Franklin RJ. Why does remyelination fail in multiple sclerosis?. Nat. Rev., Neurosci. 2002;3:705–714
  19. Giri S, Rattan R, Singh AK, Singh I. The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase–Akt–NF-kappaB–p300 pathway independent of peroxisome proliferator-activated receptor gamma. J. Immunol. 2004;173:5196–5208
  20. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today. 2000;6:88–91
  21. Hemmer B, Archelos JJ, Hartung H. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev., Neurosci. 2002;4:291–301
  22. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokine. Nature. 1998;391:82–86
  23. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, et al. 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 2000;106:189–197
  24. Kliewer SA, Willson TM. The nuclear receptor PPAR-bigger than fat. Curr. Opin. Genet. Dev. 1998;8:576–581
  25. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997;11:779–791
  26. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ). J. Biol. Chem. 1995;270:12953–12956
  27. Mukherjee R, Jow L, Croston GE, Paterniti JR. Identification, characterization and tissue distribution of human peroxisome proliferator activated receptor isoforms 1 and 2 and activation with retinoid×receptor agonists and antagonists. J. Biol. Chem. 1997;272:8071–8076
  28. Muthian G, Bright JJ. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol. 2004;24(5):542–552
  29. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 2002;3:59–70
  30. Natarajan C, Muthian G, Barak Y, Evans RM, Bright JJ. Peroxisome proliferator-activated receptor-gamma deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J. Immunol. 2003;171:5743–5750
  31. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 2000;60:1245–1250
  32. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of PPARγ. J. Neuroimmunol. 2001;116:40–48
  33. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 2000;343:938–952
  34. Owens T, Sriram S. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Neurol. Clin. 1995;13:51–73
  35. Raikwar HP, Muthian G, Rajasingh J, Johnson C, Bright JJ. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis. J. Neuroimmunol. 2005;167:99–107
  36. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79–82
  37. Rockwell CE, Kaminski NE. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther. 2004;311:683–690
  38. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karen M, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 2000;403:103–108
  39. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 2005;65:2251–2259
  40. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J. Leukocyte Biol. 2004;75:478–485
  41. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N. Engl. J. Med. 1998;338:861–866
  42. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, et al. Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands. Anal. Biochem. 2005;344:8–15
  43. Shimizu T, Szalay L, Hsieh YC, Choudhary MA, Bland KI, Chaudry IH. Salutary effects of androstenediol on hepatic function after trauma-hemorrhage are mediated via peroxisome proliferators-activated receptor gamma. Surgery. 2005;138:204–211
  44. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev. Neurosci. 2002;25:491–505
  45. Willson TM, Wahli W. Peroxisome proliferator activated receptor agonists. Cur. Opin. Chem. Biol. 1997;1:235–241
  46. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab. Invest. 2001;81:263–281
  47. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 2000;275:1873–1877

PII: S0165-5728(06)00194-9

doi: 10.1016/j.jneuroim.2006.05.013

Journal of Neuroimmunology
Volume 178, Issue 1 , Pages 76-86 , September 2006

Article Tools

* Image Usage & Resolution